Meeting
2011 ASCO Annual Meeting
Induction of apoptosis by the BRAFV600E kinase inhibitor PLX4032 in BRAFV600E melanoma cells through regulation of endoplasmic reticulum stress-related genes.
Authors
F. E. Meier
University of Tuebingen, Tuebingen, Germany
F. E. Meier , D. Beck , H. Niessner , K. T. Flaherty , J. Iovanna , D. Kulms , D. Schadendorf , C. Garbe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma
Citation
J Clin Oncol 29: 2011 (suppl; abstr 8518)
Abstract #
8518
Poster Bd #
6
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Effect of the BRAF inhibitor LGX818 on endoplasmic reticulum stress and sensitivity of NRAS-mutant melanoma cells to the MEK inhibitor binimetinib.
First Author: Friedegund Elke Meier
Poster
2023 ASCO Annual Meeting
A powerful drug combination strategy targeting BRAF-mutant melanoma.
First Author: Luke Daniel Rothermel
Poster
2021 ASCO Annual Meeting
Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.
First Author: Maria Gonzalez-Cao
Poster
2018 ASCO Annual Meeting
Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): Implications for combination with immunotherapy.
First Author: Suthee Rapisuwon